Profile data is unavailable for this security.
About the company
Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.
- Revenue in EUR (TTM)1.87bn
- Net income in EUR365.90m
- Incorporated1989
- Employees11.79k
- LocationKrka dd Novo MestoSmarjeska cesta 6NOVO MESTO 8501SloveniaSVN
- Phone+386 73312111
- Fax+386 73321537
- Websitehttps://www.krka.si/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ajanta Pharma Ltd | 490.67m | 95.60m | 4.07bn | 7.84k | 42.91 | 10.14 | 36.84 | 8.30 | 69.55 | 69.55 | 356.94 | 294.36 | 0.9738 | 1.33 | 4.16 | 5,725,128.00 | 18.97 | 16.61 | 23.29 | 20.47 | 75.77 | 73.22 | 19.48 | 19.31 | 2.13 | 49.88 | 0.0088 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| ADMA Biologics Inc | 303.60m | 31.98m | 4.09bn | 624.00 | 135.91 | 23.65 | 103.22 | 13.49 | 0.1406 | 0.1406 | 1.41 | 0.8079 | 0.9181 | 1.04 | 9.88 | 529,237.60 | 9.67 | -24.80 | 10.99 | -28.00 | 46.12 | 17.40 | 10.53 | -51.31 | 2.80 | 4.59 | 0.4105 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Xiamen Amoytop Biotech Co Ltd | 336.06m | 95.91m | 4.10bn | 1.96k | 42.77 | 13.99 | -- | 12.21 | 1.82 | 1.82 | 6.38 | 5.57 | 1.08 | 0.8928 | 6.18 | 1,324,099.00 | 30.73 | 17.96 | 35.90 | 21.02 | 92.71 | 90.48 | 28.54 | 19.17 | 3.60 | -- | 0.0044 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| China Resources Pharmaceutical Group Ltd | 32.36bn | 487.60m | 4.18bn | 72.76k | 8.56 | 0.6685 | 2.80 | 0.129 | 0.6562 | 0.6562 | 43.55 | 8.41 | 0.966 | 6.09 | 3.28 | 3,748,829.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Aspen Pharmacare Holdings Limited | 2.34bn | 230.97m | 4.23bn | 8.87k | 18.24 | 0.9467 | 12.66 | 1.81 | 9.91 | 9.91 | 100.64 | 191.03 | 0.327 | 1.34 | 3.48 | 5,041,841.00 | 3.22 | 3.92 | 3.90 | 4.90 | 43.52 | 46.88 | 9.85 | 12.43 | 1.07 | 7.93 | 0.3005 | 23.46 | 9.82 | 4.71 | -15.76 | 21.27 | 9.09 | -- |
| Kalbe Farma Tbk PT | 1.87bn | 179.76m | 4.35bn | 12.92k | 23.82 | 3.31 | 19.29 | 2.32 | 66.76 | 66.76 | 696.65 | 480.69 | 1.15 | 2.93 | 6.43 | 2,450,938,000.00 | 11.09 | 12.50 | 14.03 | 15.48 | 37.46 | 41.21 | 9.65 | 11.26 | 2.56 | -- | 0.0302 | 50.53 | 5.24 | 7.64 | -18.20 | 2.40 | -3.00 | 3.58 |
| BridgeBio Pharma Inc | 201.45m | -417.21m | 4.36bn | 550.00 | -- | -- | -- | 21.62 | -2.64 | -2.64 | 1.24 | -5.81 | 0.3376 | -- | -- | 398,407.30 | -71.11 | -72.44 | -89.59 | -89.72 | 98.91 | 94.41 | -210.62 | -1,225.66 | -- | -9.63 | 2.70 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| ALK-Abello A/S | 694.60m | 92.52m | 4.39bn | 2.81k | 52.29 | 7.28 | 32.95 | 6.32 | 3.09 | 3.09 | 22.91 | 22.22 | 0.7673 | 1.27 | 6.11 | 1,834,278.00 | 10.22 | 3.50 | 12.56 | 4.37 | 63.42 | 60.66 | 13.32 | 5.07 | 1.29 | 479.50 | 0.0934 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| IPCA Laboratories Ltd | 897.31m | 63.02m | 4.39bn | 17.34k | 69.73 | -- | 42.39 | 4.90 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| Krka d.d. Novo Mesto | 1.87bn | 365.90m | 4.46bn | 11.79k | 11.48 | 1.75 | 9.62 | 2.38 | 11.85 | 11.85 | 60.59 | 77.51 | 0.6476 | 1.40 | 3.59 | 160,399.30 | 12.64 | 12.64 | 14.86 | 15.12 | 56.10 | 57.29 | 19.52 | 18.71 | 3.04 | -- | 0.005 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
| Humanwell Healthcare Group Co Ltd | 3.31bn | 253.22m | 4.47bn | 17.68k | 17.47 | 1.93 | -- | 1.35 | 1.21 | 1.21 | 15.87 | 10.95 | 0.6902 | 3.80 | 2.74 | 1,445,825.00 | 7.13 | 6.20 | 13.12 | 12.72 | 45.59 | 42.82 | 10.33 | 9.84 | 1.21 | 12.09 | 0.3171 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Rohto Pharmaceutical Co Ltd | 1.68bn | 183.26m | 4.75bn | 7.26k | 25.11 | 2.95 | 19.88 | 2.83 | 132.56 | 132.56 | 1,215.22 | 1,129.95 | 0.7642 | 2.21 | 4.37 | 38,300,730.00 | 8.42 | 8.54 | 11.70 | 11.79 | 57.76 | 58.59 | 11.02 | 10.30 | 1.27 | -- | 0.1513 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
| Corcept Therapeutics Incorporated | 577.85m | 130.38m | 4.82bn | 352.00 | 39.43 | 8.18 | 36.69 | 8.34 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Data as of Nov 05 2024. Currency figures normalised to Krka dd Novo Mesto's reporting currency: Euro EUR
14.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kapitalska druzba ddas of 31 Dec 2023 | 3.57m | 10.90% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 335.26k | 1.02% |
| Schroder Investment Management Ltd.as of 30 Jun 2024 | 199.39k | 0.61% |
| Mawer Investment Management Ltd.as of 30 Jun 2024 | 190.27k | 0.58% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 132.10k | 0.40% |
| Trigon Asset Management ASas of 30 Jun 2024 | 60.45k | 0.18% |
| Discover Capital GmbHas of 30 Jun 2024 | 50.00k | 0.15% |
| Swedbank Robur Fonder ABas of 30 Sep 2024 | 46.39k | 0.14% |
| Triglav Skladi dooas of 31 Dec 2023 | 41.99k | 0.13% |
| HSBC Global Asset Management (UK) Ltd.as of 31 Aug 2024 | 37.79k | 0.12% |
More ▼
Data from 31 Dec 2023 - 01 Oct 2024Source: FactSet Research Systems Inc.
